|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
CA2539253A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
US9895444B2
(en)
|
2004-08-25 |
2018-02-20 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
|
US20140162965A1
(en)
|
2004-08-25 |
2014-06-12 |
Aegis Therapeutics, Inc. |
Compositions for oral drug administration
|
|
US20060046962A1
(en)
|
2004-08-25 |
2006-03-02 |
Aegis Therapeutics Llc |
Absorption enhancers for drug administration
|
|
US8268791B2
(en)
*
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
|
JP5107713B2
(ja)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー／エス |
遅延性のエキセンディン−４化合物
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
TWI372629B
(en)
*
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
BRPI0608516A2
(pt)
*
|
2005-03-18 |
2010-11-16 |
Novo Nordisk As |
análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
ES2426445T3
(es)
|
2006-04-07 |
2013-10-23 |
Merrion Research Iii Limited |
Forma de dosificación oral sólida que contiene un potenciador
|
|
US7998927B2
(en)
*
|
2006-06-23 |
2011-08-16 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US7425542B2
(en)
*
|
2006-06-23 |
2008-09-16 |
Aegis Therapeutics, Inc. |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US20090326193A1
(en)
*
|
2006-06-23 |
2009-12-31 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US8084022B2
(en)
*
|
2006-06-23 |
2011-12-27 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US8226949B2
(en)
*
|
2006-06-23 |
2012-07-24 |
Aegis Therapeutics Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US8173594B2
(en)
*
|
2006-06-23 |
2012-05-08 |
Aegis Therapeutics, Llc |
Stabilizing alkylglycoside compositions and methods thereof
|
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
|
US20100261637A1
(en)
*
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
ES2672770T3
(es)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
|
ES2612736T3
(es)
|
2007-11-16 |
2017-05-18 |
Novo Nordisk A/S |
Composiciones farmacéuticas estables que comprenden liraglutida y degludec
|
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
MX2010009850A
(es)
|
2008-03-18 |
2010-09-30 |
Novo Nordisk As |
Analogos de insulina acilados y etabilizados contra proteasas.
|
|
ES2586032T3
(es)
|
2008-03-28 |
2016-10-11 |
Hale Biopharma Ventures, Llc |
Administración de composiciones de benzodiazepinas
|
|
WO2009137080A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of gnrh related compounds and processes of preparation
|
|
MX2011000847A
(es)
*
|
2008-08-06 |
2011-02-25 |
Novo Nordisk Healthcare Ag |
Proteinas conjugadas con eficacia prolongada in vivo.
|
|
CN106317164A
(zh)
|
2008-09-12 |
2017-01-11 |
诺沃—诺迪斯克有限公司 |
酰化肽或蛋白的方法
|
|
US8440631B2
(en)
|
2008-12-22 |
2013-05-14 |
Aegis Therapeutics, Llc |
Compositions for drug administration
|
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
|
ES2692495T3
(es)
|
2009-01-23 |
2018-12-03 |
Novo Nordisk A/S |
Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
|
|
US20120172298A1
(en)
*
|
2009-06-11 |
2012-07-05 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
ME02220B
(me)
|
2009-07-13 |
2016-02-20 |
Zealand Pharma As |
Analozi acilovanog glukagona
|
|
WO2011015649A1
(en)
|
2009-08-06 |
2011-02-10 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
|
CN104327182B
(zh)
*
|
2009-12-16 |
2020-04-17 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
|
BR112012018162A2
(pt)
|
2010-01-22 |
2017-10-03 |
Novo Nordisk Healthcare Ag |
Compostos de hormônio do crescimento estáveis
|
|
CN118767117A
(zh)
|
2010-01-22 |
2024-10-15 |
诺沃—诺迪斯克保健股份有限公司 |
体内功效延长的生长激素
|
|
US20130012432A1
(en)
|
2010-02-26 |
2013-01-10 |
Novo Nordisk A/S |
Peptides for Treatment of Obesity
|
|
US20130143798A1
(en)
*
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
|
CN102186881B
(zh)
*
|
2010-04-27 |
2015-04-08 |
贝达药业股份有限公司 |
胰高血糖素样肽-1衍生物及其应用
|
|
RU2531590C2
(ru)
*
|
2010-04-27 |
2014-10-20 |
Бета Фармасьютикалс,Ко,Лтд. |
Аналоги глюкагоноподобного пептида-1 и их применение
|
|
WO2011143788A1
(en)
*
|
2010-05-17 |
2011-11-24 |
Zhejiang Beta Pharma Inc. |
Novel glucagon like peptide analogs, composition, and method of use
|
|
WO2012016419A1
(zh)
*
|
2010-08-06 |
2012-02-09 |
浙江贝达药业有限公司 |
Glp-1衍生物及其应用
|
|
CN105601729A
(zh)
|
2010-11-09 |
2016-05-25 |
诺沃—诺迪斯克有限公司 |
双-酰化的glp-1衍生物
|
|
MX345501B
(es)
|
2010-12-16 |
2017-02-02 |
Novo Nordisk As |
Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
|
|
US8802114B2
(en)
|
2011-01-07 |
2014-08-12 |
Merrion Research Iii Limited |
Pharmaceutical compositions of iron for oral administration
|
|
US20140045754A1
(en)
|
2011-01-19 |
2014-02-13 |
Joern Drustrup |
Glp-1 compositions
|
|
US20140004198A1
(en)
|
2011-01-19 |
2014-01-02 |
Novo Nordisk A/S |
Glp-1 particles and compositions
|
|
KR20140020292A
(ko)
*
|
2011-03-28 |
2014-02-18 |
노보 노르디스크 에이/에스 |
신규 글루카곤 유사체
|
|
JP5871905B2
(ja)
*
|
2011-03-30 |
2016-03-01 |
ベータ ファーマシューティカルズ カンパニー リミテッド |
グルカゴン様ペプチド−１類似体およびその使用
|
|
KR101972836B1
(ko)
*
|
2011-04-12 |
2019-04-29 |
노보 노르디스크 에이/에스 |
이중 아실화된 ｇｌｐ-1 유도체
|
|
KR102093463B1
(ko)
*
|
2011-04-12 |
2020-03-26 |
노보 노르디스크 에이/에스 |
이중 아실화된 ｇｌｐ-1 유도체
|
|
CN103796656A
(zh)
|
2011-06-14 |
2014-05-14 |
哈尔生物药投资有限责任公司 |
苯二氮卓的投与
|
|
CN103930134B
(zh)
|
2011-07-18 |
2016-12-21 |
阿茨生物股份有限公司 |
长效促黄体激素(lh)化合物
|
|
JP6126097B2
(ja)
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体
|
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー／エス |
新規のグルカゴン類似体
|
|
AU2012360998B2
(en)
|
2011-12-29 |
2017-11-23 |
Novo Nordisk A/S |
Dipeptide comprising a non-proteogenic amino acid
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
LT2814842T
(lt)
|
2012-02-15 |
2018-11-12 |
Novo Nordisk A/S |
Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
|
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
|
WO2013139695A1
(en)
|
2012-03-22 |
2013-09-26 |
Novo Nordisk A/S |
Compositions comprising a delivery agent and preparation thereof
|
|
EP2827885B1
(en)
|
2012-03-22 |
2018-08-15 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
|
HRP20190489T1
(hr)
|
2012-03-22 |
2019-05-03 |
Novo Nordisk A/S |
Pripravci koji sadrže sredstvo za unošenje i njihova priprava
|
|
PT2827885T
(pt)
*
|
2012-03-22 |
2018-11-05 |
Novo Nordisk As |
Composições de péptidos glp-1 e sua preparação
|
|
WO2013164483A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
JP6250034B2
(ja)
|
2012-05-08 |
2017-12-20 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
JP6366575B2
(ja)
|
2012-05-08 |
2018-08-01 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
US9745359B2
(en)
|
2012-05-18 |
2017-08-29 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
US9993430B2
(en)
*
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
|
HRP20251088T1
(hr)
|
2012-07-01 |
2025-11-07 |
Novo Nordisk A/S |
Upotreba dugodjelujućih peptida glp‑1
|
|
MY170671A
(en)
|
2012-07-23 |
2019-08-26 |
Zealand Pharma As |
Glucagon analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
US20150273069A1
(en)
*
|
2012-10-17 |
2015-10-01 |
Novo Nordisk A/S |
Fatty acid acylated amino acids for oral peptide delivery
|
|
CN105120887A
(zh)
|
2013-04-05 |
2015-12-02 |
诺和诺德保健股份有限公司 |
生长激素化合物制剂
|
|
PL2986313T3
(pl)
|
2013-04-18 |
2019-12-31 |
Novo Nordisk A/S |
Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
|
|
SMT201800492T1
(it)
|
2013-05-02 |
2018-11-09 |
Novo Nordisk As |
Dosaggio orale di composti di glp-1
|
|
EP3010546B1
(en)
|
2013-06-20 |
2017-08-09 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
BR112015032875A2
(pt)
|
2013-07-04 |
2017-11-07 |
Novo Nordisk As |
derivados de peptídeos do tipo glp-1, e usos dos mesmos
|
|
US10266577B2
(en)
|
2013-08-15 |
2019-04-23 |
Novo Nordisk A/S |
GLP-1 derivatives, and uses thereof
|
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
|
US10286078B2
(en)
|
2013-09-13 |
2019-05-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
SI3057984T1
(sl)
|
2013-10-17 |
2018-10-30 |
Zealand Pharma A/S |
Acilirani glukagonski analogi
|
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
|
US10093713B2
(en)
*
|
2013-11-06 |
2018-10-09 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
CA2933701C
(en)
*
|
2013-12-18 |
2022-05-31 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
AR100306A1
(es)
|
2014-02-18 |
2016-09-28 |
Novo Nordisk As |
Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
|
|
ES2741507T3
(es)
|
2014-04-07 |
2020-02-11 |
Novo Nordisk As |
Compuestos de glp-1 acilados doblemente
|
|
WO2015169789A1
(en)
|
2014-05-07 |
2015-11-12 |
Novo Nordisk A/S |
Treatment of diabetes type 1 using glp-1 and anti-il-21
|
|
EP3151852A1
(en)
|
2014-06-04 |
2017-04-12 |
Novo Nordisk A/S |
Glp-1/glucagon receptor co-agonists for medical use
|
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
|
GR20140100479A
(el)
*
|
2014-09-23 |
2016-05-05 |
Novetide, Ltd., |
Συνθεση λιραγλουτιδης
|
|
EP3006045B3
(en)
|
2014-10-07 |
2021-03-17 |
Cyprumed GmbH |
Pharmaceutical formulations for the oral delivery of peptide or protein drugs
|
|
TWI705973B
(zh)
|
2014-10-29 |
2020-10-01 |
丹麥商西蘭製藥公司 |
Ｇｉｐ促效劑化合物及方法
|
|
JP6730278B2
(ja)
*
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
US10392428B2
(en)
|
2014-12-17 |
2019-08-27 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
HUE044783T2
(hu)
|
2014-12-23 |
2019-11-28 |
Novo Nordisk As |
FGF21 származékok és alkalmazásaik
|
|
US20180263915A1
(en)
*
|
2015-01-29 |
2018-09-20 |
Novo Nordisk A/S |
Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
|
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
|
|
TWI707867B
(zh)
*
|
2015-04-16 |
2020-10-21 |
丹麥商西蘭製藥公司 |
醯化之昇糖素類似物
|
|
US20180169010A1
(en)
*
|
2015-06-16 |
2018-06-21 |
Sun Pharma Advanced Research Company Limited |
Long acting liraglutide compositions
|
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
CN106554403B
(zh)
*
|
2015-09-25 |
2021-08-31 |
博瑞生物医药（苏州）股份有限公司 |
艾塞那肽修饰物及其用途
|
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
|
CN106554408A
(zh)
*
|
2015-09-30 |
2017-04-05 |
天津药物研究院有限公司 |
长效胰高血糖素样肽-1类似物二聚体及其应用
|
|
CA2997343A1
(en)
|
2015-10-07 |
2017-04-13 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
|
CN106928343A
(zh)
*
|
2015-12-30 |
2017-07-07 |
深圳翰宇药业股份有限公司 |
索玛鲁肽的制备方法
|
|
ES2835033T3
(es)
|
2016-03-03 |
2021-06-21 |
Novo Nordisk As |
Derivados de GLP-1 y sus usos
|
|
CN107266557B
(zh)
*
|
2016-04-06 |
2020-04-07 |
天津药物研究院有限公司 |
一种聚乙二醇修饰的胰高血糖素样肽-1类似物
|
|
KR20180135012A
(ko)
*
|
2016-04-28 |
2018-12-19 |
노보 노르디스크 에이/에스 |
심혈관 병태에서의 세마글루타이드
|
|
WO2018065634A1
(en)
|
2016-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
|
|
WO2018078112A1
(en)
|
2016-10-27 |
2018-05-03 |
Aarhus Universitet |
Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis
|
|
MA46780A
(fr)
|
2016-11-07 |
2019-09-11 |
Novo Nordisk As |
Esters à dchbs actif de composés peg et leur utilisation
|
|
MA49116A
(fr)
|
2016-12-16 |
2020-03-25 |
Novo Nordisk As |
Compositions pharmaceutiques contenant de l'insuline
|
|
CN107033234B
(zh)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
酰化的glp-1衍生物
|
|
WO2018165462A1
(en)
|
2017-03-08 |
2018-09-13 |
Intarcia Therapeutics, Inc |
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
|
|
BR112019025195A8
(pt)
|
2017-05-31 |
2020-07-07 |
Univ Copenhagen |
análogos do peptídeo gip de ação prolongada
|
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
|
CN109248323B
(zh)
*
|
2017-07-14 |
2023-09-08 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
|
EP3655427A1
(en)
*
|
2017-07-19 |
2020-05-27 |
Novo Nordisk A/S |
Bifunctional compounds
|
|
TWI847306B
(zh)
*
|
2017-08-24 |
2024-07-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Ｇｌｐ-１組成物及其用途
|
|
JP2020533302A
(ja)
|
2017-09-10 |
2020-11-19 |
ノヴォ ノルディスク アー／エス |
肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
|
|
JP7377195B2
(ja)
|
2017-09-29 |
2023-11-09 |
ハンミ ファーマシューティカル カンパニー リミテッド |
リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法
|
|
IL322969A
(en)
|
2017-10-12 |
2025-10-01 |
Novo Nordisk As |
Semaglutide in medical therapy
|
|
CN107881187A
(zh)
*
|
2017-11-20 |
2018-04-06 |
珠海联邦制药股份有限公司 |
将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
|
|
US11186608B2
(en)
|
2017-12-21 |
2021-11-30 |
Bachem Holding Ag |
Solid phase synthesis of acylated peptides
|
|
EP4299118A3
(en)
|
2018-02-02 |
2024-04-10 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
|
|
JP6941224B2
(ja)
|
2018-02-06 |
2021-09-29 |
イージス セラピューティクス，エルエルシー |
疾患の処置のための鼻腔内エピネフリン製剤及び方法
|
|
CN110294800B
(zh)
*
|
2018-03-22 |
2022-03-04 |
齐鲁制药有限公司 |
一种索玛鲁肽的制备方法
|
|
TWI790370B
(zh)
|
2018-04-02 |
2023-01-21 |
美商必治妥美雅史谷比公司 |
抗trem-1抗體及其用途
|
|
ES2980707T3
(es)
*
|
2018-04-05 |
2024-10-02 |
Sun Pharmaceutical Ind Ltd |
Nuevos análogos de GLP-1
|
|
EP3773475A1
(en)
|
2018-04-06 |
2021-02-17 |
Cyprumed GmbH |
Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
|
|
WO2019200594A1
(zh)
*
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
|
CN115814063A
(zh)
*
|
2018-04-19 |
2023-03-21 |
杭州先为达生物科技有限公司 |
Glp-1衍生物及其治疗用途
|
|
TWI707865B
(zh)
|
2018-05-04 |
2020-10-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Gip衍生物及其用途
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
JP7422754B2
(ja)
*
|
2018-10-26 |
2024-01-26 |
ノヴォ ノルディスク アー／エス |
安定性セマグルチド組成物およびその使用
|
|
CN109180801B
(zh)
*
|
2018-11-01 |
2021-08-13 |
汉肽生物医药集团有限公司 |
一种合成索玛鲁肽的方法
|
|
US12297250B2
(en)
|
2018-12-03 |
2025-05-13 |
Antag Therapeutics Aps |
Modified GIP peptide analogues
|
|
EP3897570A1
(en)
|
2018-12-19 |
2021-10-27 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition comprising glp-1 analogue
|
|
MA54510A
(fr)
|
2018-12-21 |
2022-03-30 |
Novo Nordisk As |
Procédé de séchage par pulvérisation de peptide glp-1
|
|
JP7560467B2
(ja)
|
2019-01-24 |
2024-10-02 |
ノヴォ ノルディスク アー／エス |
ローラコンパクタおよびローラコンパクタを使用する乾式造粒の方法
|
|
AU2020223031B2
(en)
|
2019-02-12 |
2024-08-29 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
|
JP7495420B2
(ja)
|
2019-02-20 |
2024-06-04 |
ノヴォ ノルディスク アー／エス |
アミノアシル－ｔＲＮＡ合成酵素およびこの使用
|
|
EP3930757A1
(en)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
WO2020190757A1
(en)
|
2019-03-15 |
2020-09-24 |
Novetide Ltd. |
Improved processes for the preparation of semaglutide
|
|
CN113631251B
(zh)
*
|
2019-03-15 |
2025-04-25 |
诺和诺德股份有限公司 |
Glp-1肽的喷雾干燥工艺
|
|
CN111748019A
(zh)
*
|
2019-03-29 |
2020-10-09 |
深圳翰宇药业股份有限公司 |
一种多肽衍生化合物的合成方法
|
|
CN120518763A
(zh)
|
2019-04-01 |
2025-08-22 |
诺和诺德股份有限公司 |
针对利拉鲁肽的抗体及其用途
|
|
CA3136163A1
(en)
*
|
2019-04-11 |
2020-10-15 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Multi-receptor agonist and medical use thereof
|
|
CN111909256A
(zh)
*
|
2019-05-10 |
2020-11-10 |
宁波鲲鹏生物科技有限公司 |
多肽衍生物及其制备方法
|
|
BR112021023012A2
(pt)
*
|
2019-05-21 |
2022-01-04 |
Medimmune Ltd |
Coformulações injetáveis à base de ciclodextrina de inibidores de sglt2 e peptídeos de incretina
|
|
EP4025192B1
(en)
|
2019-09-02 |
2025-12-03 |
Novo Nordisk A/S |
Process for producing a tablet comprising glp-1 peptides
|
|
WO2021055497A1
(en)
*
|
2019-09-16 |
2021-03-25 |
Biomarin Pharmaceutical Inc. |
Cnp variants and conjugates thereof
|
|
CN110590934B
(zh)
*
|
2019-09-25 |
2020-12-08 |
北京乐普医药科技有限公司 |
一种glp-1化合物
|
|
CN114728042A
(zh)
|
2019-11-06 |
2022-07-08 |
诺和诺德股份有限公司 |
用于痴呆的glp-1受体激动剂
|
|
EP3819308A1
(en)
|
2019-11-07 |
2021-05-12 |
Fresenius Kabi iPSUM S.r.l. |
Process for the manufacture of derivatized amino acids
|
|
CN114641276A
(zh)
|
2019-11-07 |
2022-06-17 |
诺和诺德股份有限公司 |
包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
|
|
WO2021105393A1
(en)
|
2019-11-29 |
2021-06-03 |
Novo Nordisk A/S |
Processes for obtaining stable glp-1 compositions
|
|
WO2021123228A1
(en)
|
2019-12-18 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising glp-1 analogue
|
|
CN119060162A
(zh)
*
|
2019-12-30 |
2024-12-03 |
甘李药业股份有限公司 |
长效glp-1化合物
|
|
WO2021136223A1
(en)
|
2019-12-31 |
2021-07-08 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
CN115322794B
(zh)
|
2020-01-11 |
2025-09-19 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
FI4097099T3
(fi)
|
2020-02-07 |
2024-07-30 |
Gasherbrum Bio Inc |
Heterosyklisiä glp-1-agonisteja
|
|
CA3167978A1
(en)
|
2020-02-14 |
2021-08-19 |
Yongha NA |
Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
|
|
CN111253475B
(zh)
*
|
2020-02-18 |
2021-03-09 |
江苏诺泰澳赛诺生物制药股份有限公司 |
Glp-1激动多肽化合物及其盐与合成方法及用途
|
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|
|
WO2021205388A2
(en)
|
2020-04-10 |
2021-10-14 |
Fresenius Kabi Oncology Limited |
An improved process for the preparation of semaglutide side chain
|
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
|
PL4143183T3
(pl)
|
2020-04-29 |
2026-03-02 |
Gasherbrum Bio, Inc. |
Heterocykliczni agoniści glp-1
|
|
US20230165939A1
(en)
|
2020-04-29 |
2023-06-01 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and histidine
|
|
AR122579A1
(es)
*
|
2020-06-12 |
2022-09-21 |
Lilly Co Eli |
Proceso para preparar un agonista dual glp-1 / glucagón
|
|
WO2022018185A1
(en)
|
2020-07-22 |
2022-01-27 |
Novo Nordisk A/S |
Glp-1 and gip receptor co-agonists
|
|
MX2023001311A
(es)
|
2020-08-06 |
2023-04-18 |
Gasherbrum Bio Inc |
Agonistas heterociclicos de glp-1.
|
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
|
WO2022049310A1
(en)
|
2020-09-07 |
2022-03-10 |
Cyprumed Gmbh |
Improved pharmaceutical formulations of glp-1 receptor agonists
|
|
JP2023545684A
(ja)
*
|
2020-09-30 |
2023-10-31 |
ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド |
ポリペプチドコンジュゲートおよび使用の方法
|
|
PE20240630A1
(es)
|
2020-11-06 |
2024-03-26 |
Novo Nordisk As |
Profarmacos de glp-1 y usos de los mismos
|
|
TW202440619A
(zh)
|
2020-12-18 |
2024-10-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
EP4317179B1
(en)
|
2021-03-25 |
2025-10-29 |
BrightGene Bio-Medical Technology Co., Ltd. |
Gip and glp-1 dual receptor agonist, pharmaceutical composition, and use
|
|
EP4313163A1
(en)
|
2021-04-03 |
2024-02-07 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
|
TW202304500A
(zh)
|
2021-04-21 |
2023-02-01 |
瑞士商諾華公司 |
升糖素樣肽化合物
|
|
CN117794946A
(zh)
|
2021-06-09 |
2024-03-29 |
斯克利普斯研究所 |
长效双重gip/glp-1肽缀合物及使用方法
|
|
KR20240021212A
(ko)
|
2021-06-10 |
2024-02-16 |
안타그 테라퓨틱스 에이피에스 |
비만 및 비만-관련 장애의 치료
|
|
KR102815534B1
(ko)
|
2021-06-23 |
2025-06-02 |
주식회사 펩트론 |
세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물
|
|
EP4360645A4
(en)
*
|
2021-06-25 |
2025-09-10 |
Gan & Lee Pharmaceuticals Co Ltd |
PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND
|
|
CN117580583A
(zh)
|
2021-06-25 |
2024-02-20 |
甘李药业股份有限公司 |
Pcsk9抑制剂和glp-1受体激动剂的药物组合
|
|
WO2023285334A1
(en)
|
2021-07-12 |
2023-01-19 |
Novo Nordisk A/S |
Novel fatty acid modified urocortin 2 derivatives and the uses thereof
|
|
CA3224743A1
(en)
|
2021-07-14 |
2023-01-19 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion polypeptides for metabolic disorders
|
|
MX2024000768A
(es)
|
2021-07-15 |
2024-02-12 |
Novo Nordisk As |
Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
|
|
CN113429471B
(zh)
*
|
2021-07-19 |
2022-12-23 |
青岛博睿精创科技有限公司 |
长效glp-1多肽类似物及其制备方法和应用
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
CN118215478A
(zh)
|
2021-09-08 |
2024-06-18 |
盐野义制药株式会社 |
用于预防和治疗与抗肥胖作用有关的疾病的药物
|
|
WO2023086499A1
(en)
|
2021-11-10 |
2023-05-19 |
I2O Therapeutics, Inc. |
Ionic liquid compositions
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
WO2023110833A1
(en)
|
2021-12-13 |
2023-06-22 |
Novo Nordisk A/S |
Pharmaceutical formulations comprising a cyclodextrin
|
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
|
EP4496797A1
(en)
|
2022-03-21 |
2025-01-29 |
Gasherbrum Bio, Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
|
EP4323413A4
(en)
|
2022-03-30 |
2025-10-15 |
Beijing Ql Biopharmaceutical Co Ltd |
LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
|
|
WO2023187067A1
(en)
|
2022-03-30 |
2023-10-05 |
Novo Nordisk A/S |
Formulation method
|
|
US20250250269A1
(en)
|
2022-04-14 |
2025-08-07 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
|
CN119173275A
(zh)
|
2022-05-10 |
2024-12-20 |
诺和诺德股份有限公司 |
Glp-1多肽的前药及其用途
|
|
CA3249311A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
|
|
IL318154A
(en)
|
2022-07-05 |
2025-03-01 |
G2Gbio Inc |
A composition containing a microsphere for sustained release of semaglutide pharmaceutical salt and methods for making the same
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
|
WO2024079043A1
(en)
|
2022-10-10 |
2024-04-18 |
Bachem Holding Ag |
Method of manufacturing a peptide with a lysine derivative
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
WO2024110614A1
(en)
|
2022-11-25 |
2024-05-30 |
Novo Nordisk A/S |
Oral administration of peptide therapeutics, such as glp-1
|
|
WO2024128882A1
(ko)
|
2022-12-16 |
2024-06-20 |
주식회사 펩트론 |
Glp-1 수용체 작용제 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구 및 이의 용도
|
|
CN116159027A
(zh)
*
|
2022-12-29 |
2023-05-26 |
江苏诺泰澳赛诺生物制药股份有限公司 |
一种司美格鲁肽冻干药物组合物及其制备方法
|
|
AU2023415591A1
(en)
|
2022-12-30 |
2025-08-14 |
Algipharma As |
Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
CN120731085A
(zh)
*
|
2023-03-02 |
2025-09-30 |
甘李药业股份有限公司 |
一种glp-1化合物的医药用途
|
|
KR20250131829A
(ko)
|
2023-03-06 |
2025-09-03 |
아센디스 파마 에이에스 |
알부민 결합 모이어티를 포함하는 약물 화합물
|
|
AU2024232125A1
(en)
|
2023-03-06 |
2025-08-28 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
AU2024233842A1
(en)
|
2023-03-06 |
2025-09-04 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
WO2024199734A2
(en)
|
2023-03-30 |
2024-10-03 |
Novo Nordisk A/S |
Fusion compounds and uses thereof
|
|
WO2024234320A1
(zh)
*
|
2023-05-17 |
2024-11-21 |
南京知和医药科技有限公司 |
一种长效胰高血糖素样肽-1衍生物及其制备方法和用途
|
|
KR20260022948A
(ko)
|
2023-06-09 |
2026-02-20 |
썬 파마슈티컬 인더스트리스 리미티드 |
Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
|
|
AR132977A1
(es)
|
2023-06-15 |
2025-08-13 |
Novo Nordisk As |
Formulaciones farmacéuticas que comprenden una ciclodextrina
|
|
WO2025069009A1
(en)
|
2023-09-29 |
2025-04-03 |
Graviton Bioscience Bv |
Rock2 inhibitors in the treatment of obesity
|
|
WO2025078040A1
(en)
|
2023-10-09 |
2025-04-17 |
Bachem Holding Ag |
Lysine salt and method of manufacturing a lysine derivative
|
|
WO2025077751A1
(zh)
*
|
2023-10-09 |
2025-04-17 |
甘李药业股份有限公司 |
Glp-1肽组合物及其用途
|
|
TW202521100A
(zh)
|
2023-11-17 |
2025-06-01 |
美商雅沛尼美德公司（德拉瓦州公司） |
使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
|
|
TW202540155A
(zh)
|
2023-11-30 |
2025-10-16 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1、gip及澱粉素受體之三重促效劑
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
EP4686757A1
(en)
|
2024-07-31 |
2026-02-04 |
e-therapeutics PLC |
Inhibitors of expression and/or function
|
|
WO2025169190A2
(en)
|
2024-02-06 |
2025-08-14 |
Opko Biologics Ltd. |
Modified oxyntomodulin and methods of use thereof
|
|
EP4684801A1
(en)
|
2024-07-23 |
2026-01-28 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
WO2025172605A1
(en)
|
2024-02-16 |
2025-08-21 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4684802A1
(en)
|
2024-07-23 |
2026-01-28 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
WO2025172606A1
(en)
|
2024-02-16 |
2025-08-21 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4603079A1
(en)
|
2024-02-16 |
2025-08-20 |
Adocia |
Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
EP4603080A1
(en)
|
2024-02-16 |
2025-08-20 |
Adocia |
Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
|
|
GB202403746D0
(en)
|
2024-03-15 |
2024-05-01 |
New Roger Randal Charles |
Formulations demonstrating an oral depot effect
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|
|
WO2025231285A1
(en)
*
|
2024-05-02 |
2025-11-06 |
Kallyope, Inc. |
Peptide analogs and methods of using the same
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
WO2026008836A1
(en)
|
2024-07-05 |
2026-01-08 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|